阿普拉霉素在小鼠感染模型中的体内疗效。
In vivo efficacy of apramycin in murine infection models.
作者信息
Meyer Martin, Freihofer Pietro, Scherman Michael, Teague Joanne, Lenaerts Anne, Böttger Erik C
机构信息
Institut für Medizinische Mikrobiologie, Nationales Zentrum für Mykobakterien, Universität Zürich, Zürich, Switzerland.
Mycobacterial Research Laboratories, Department of Microbiology, Colorado State University, Fort Collins, Colorado, USA.
出版信息
Antimicrob Agents Chemother. 2014 Nov;58(11):6938-41. doi: 10.1128/AAC.03239-14. Epub 2014 Aug 18.
Abstract
Apramycin is a unique aminoglycoside with a dissociation of antibacterial activity and ototoxicity. We assessed the antibacterial efficacy of apramycin in two murine models of infection, Mycobacterium tuberculosis aerosol infection and Staphylococcus aureus septicemia. In both infection models, the efficacy of apramycin was comparable to that of amikacin. These results suggest that apramycin has the potential to become a clinically useful agent against drug-resistant pathogens and support further development of this promising unique aminoglycoside.
摘要
阿普拉霉素是一种具有独特抗菌活性和耳毒性解离特性的氨基糖苷类抗生素。我们在两种小鼠感染模型（结核分枝杆菌气溶胶感染和金黄色葡萄球菌败血症）中评估了阿普拉霉素的抗菌效果。在这两种感染模型中，阿普拉霉素的疗效与阿米卡星相当。这些结果表明，阿普拉霉素有潜力成为一种临床上对抗耐药病原体有用的药物，并支持进一步开发这种有前景的独特氨基糖苷类抗生素。
相似文献
1
In vivo efficacy of apramycin in murine infection models.
Antimicrob Agents Chemother. 2014 Nov;58(11):6938-41. doi: 10.1128/AAC.03239-14. Epub 2014 Aug 18.
2
Evaluation of apramycin activity against methicillin-resistant, methicillin-sensitive, and vancomycin-intermediate Staphylococcus aureus clinical isolates.
Diagn Microbiol Infect Dis. 2018 Oct;92(2):168-171. doi: 10.1016/j.diagmicrobio.2018.05.018. Epub 2018 May 29.
3
Apramycin Overcomes the Inherent Lack of Antimicrobial Bactericidal Activity in Mycobacterium abscessus.
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0151021. doi: 10.1128/AAC.01510-21. Epub 2021 Dec 20.
4
Efficacy of Apramycin against Multidrug-Resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model.
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02585-17. Print 2018 Apr.
5
Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin.
Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):10984-9. doi: 10.1073/pnas.1204073109. Epub 2012 Jun 14.
6
Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis.
EBioMedicine. 2021 Nov;73:103652. doi: 10.1016/j.ebiom.2021.103652. Epub 2021 Nov 2.
7
In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii.
J Antimicrob Chemother. 2019 Apr 1;74(4):944-952. doi: 10.1093/jac/dky546.
8
Apralogs: Apramycin 5--Glycosides and Ethers with Improved Antibacterial Activity and Ribosomal Selectivity and Reduced Susceptibility to the Aminoacyltranserferase (3)-IV Resistance Determinant.
J Am Chem Soc. 2020 Jan 8;142(1):530-544. doi: 10.1021/jacs.9b11601. Epub 2019 Dec 17.
9
Novel apramycin resistance gene apmA in bovine and porcine methicillin-resistant Staphylococcus aureus ST398 isolates.
Antimicrob Agents Chemother. 2011 Jan;55(1):373-5. doi: 10.1128/AAC.01124-10. Epub 2010 Sep 27.
10
Apramycin susceptibility of multidrug-resistant Gram-negative blood culture isolates in five countries in Southeast Asia.
Int J Antimicrob Agents. 2022 Oct;60(4):106659. doi: 10.1016/j.ijantimicag.2022.106659. Epub 2022 Aug 18.
引用本文的文献
1
Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects.
Pharmaceutics. 2025 Jan 15;17(1):111. doi: 10.3390/pharmaceutics17010111.
2
Overcoming (X)-harboring tigecycline resistance: a study on the efficacy of tigecycline-apramycin combinations.
Front Microbiol. 2024 Dec 23;15:1502558. doi: 10.3389/fmicb.2024.1502558. eCollection 2024.
3
Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose.
J Antimicrob Chemother. 2022 Sep 30;77(10):2718-2728. doi: 10.1093/jac/dkac225.
4
Repurposing the Veterinary Antibiotic Apramycin for Antibacterial and Antibiofilm Activity Against From Cystic Fibrosis Patients.
Front Microbiol. 2022 Feb 3;12:801152. doi: 10.3389/fmicb.2021.801152. eCollection 2021.
5
Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis.
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0050621. doi: 10.1128/AAC.00506-21. Epub 2021 Jul 12.
6
ApmA Is a Unique Aminoglycoside Antibiotic Acetyltransferase That Inactivates Apramycin.
mBio. 2021 Feb 9;12(1):e02705-20. doi: 10.1128/mBio.02705-20.
7
Apralogs: Apramycin 5--Glycosides and Ethers with Improved Antibacterial Activity and Ribosomal Selectivity and Reduced Susceptibility to the Aminoacyltranserferase (3)-IV Resistance Determinant.
J Am Chem Soc. 2020 Jan 8;142(1):530-544. doi: 10.1021/jacs.9b11601. Epub 2019 Dec 17.
8
Evaluation of apramycin against spectinomycin-resistant and -susceptible strains of Neisseria gonorrhoeae.
J Antimicrob Chemother. 2019 May 1;74(5):1311-1316. doi: 10.1093/jac/dkz012.
9
Evaluation of apramycin activity against methicillin-resistant, methicillin-sensitive, and vancomycin-intermediate Staphylococcus aureus clinical isolates.
Diagn Microbiol Infect Dis. 2018 Oct;92(2):168-171. doi: 10.1016/j.diagmicrobio.2018.05.018. Epub 2018 May 29.
10
Efficacy of Apramycin against Multidrug-Resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model.
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02585-17. Print 2018 Apr.
本文引用的文献
1
4'-O-substitutions determine selectivity of aminoglycoside antibiotics.
Nat Commun. 2014;5:3112. doi: 10.1038/ncomms4112.
2
Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.
Tuberculosis (Edinb). 2012 Nov;92(6):453-88. doi: 10.1016/j.tube.2012.07.003. Epub 2012 Aug 30.
3
Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin.
Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):10984-9. doi: 10.1073/pnas.1204073109. Epub 2012 Jun 14.
4
Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.
J Antimicrob Chemother. 2011 Aug;66(8):1815-20. doi: 10.1093/jac/dkr221. Epub 2011 Jun 3.
5
The continuing crisis in antibiotic resistance.
Int J Antimicrob Agents. 2010 Nov;36 Suppl 3:S3-7. doi: 10.1016/S0924-8579(10)70003-0.
6
Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates.
J Antimicrob Chemother. 2011 Jan;66(1):48-53. doi: 10.1093/jac/dkq408. Epub 2010 Nov 14.
7
Synthesis and spectrum of the neoglycoside ACHN-490.
Antimicrob Agents Chemother. 2010 Nov;54(11):4636-42. doi: 10.1128/AAC.00572-10. Epub 2010 Aug 30.
8
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study.
Lancet Infect Dis. 2010 Sep;10(9):597-602. doi: 10.1016/S1473-3099(10)70143-2. Epub 2010 Aug 10.
9
Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis.
Mol Microbiol. 2010 Aug;77(4):830-40. doi: 10.1111/j.1365-2958.2010.07218.x. Epub 2010 Jun 1.
10
The future of aminoglycosides: the end or renaissance?
Chembiochem. 2010 May 3;11(7):880-902. doi: 10.1002/cbic.200900779.
Zotero 插件